Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)

Market Cap	45.18B
Revenue (ttm)	8.18B
Net Income (ttm)	2.19B
Shares Out	6.60B
EPS (ttm)	0.33
PE Ratio	20.73
Forward PE	17.39
Dividend	0.04 (0.54%)
Ex-Dividend Date	Sep 30, 2024

Volume	29,742,260
Average Volume	56,270,047
Open	6.93
Previous Close	6.85
Day's Range	6.82 - 6.93
52-Week Range	6.42 - 8.68
Beta	0.54
RSI	44.85
Earnings Date	Apr 18, 2025

About SHE:002252

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 3,254
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002252

Financial Performance

In 2024, SHE:002252's revenue was 8.18 billion, an increase of 2.67% compared to the previous year's 7.96 billion. Earnings were 2.19 billion, an increase of 23.25%.